Browsing by Author "Pratheepa, K"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
ArticleItem Open Access Evaluation of Anti-tumour effects of Withaferin A Using Molecular Markers in a Rat Model of Mammary Carcinogenesis(2020-08) Pratheepa, K; Vijayarani, K; Balachandran, C; Sridhar, R; Vijay, K; TANUVASThe present study was designed to evaluate the anti-tumour potential of Withaferin A in DMBA (7,12-dimethylbenz[a]anthracene) induced rat mammary tumorigenesis. Seventy two female Sprague-Dawley rats were equally divided into control, DMBA, DMBA + tamoxifen (Standard drug) and DMBA +Withaferin A groups. DMBA (5 mg/rat/week/per os) at 4 weekly doses were used for tumour induction. Mammary tumours were collected on the 30th, 75th and 120th day after the initial dose of DMBA administration. The expression of p53, bcl-2, bax and PCNA was analysed by immunohistochemistry and RT-PCR. Oral administration of Withaferin A (16 mg/kg body weight/thrice a week/ per os) showed increased incidence of carcinomas by modulating markers of apoptosis (Bax, Bcl-2), cell survival (p53) and proliferation (PCNA) when compared to the standard drug tamoxifen (100 μg/kg body weight/day/per os).ArticleItem Open Access Histopathological evaluation of diabetic rats treated with nano vanadium(2021) Pratheepa, K; Vijaya, K; TANUVASDiabetes mellitus, a heterogeneous metabolic disorder characterized by hyperglycemia with disturbances in carbohydrate, lipid and protein metabolism. Vanadium in the form of nanoparticles has been known to exert better action as an anti-diabetic agent. This study was aimed to assess the histological changes in the liver, kidney and pancreas of STZ-induced diabetic rats following treatment with vanadium pent oxide nanoparticles. Histopathological studies on the tissues of liver, kidney and pancreas in diabetic animals showed degenerative changes and treatment with Nano vanadium was able to partially restore the degenerative changes indicating the protective effect of vanadium by normalizing biochemical and histological abnormalities in diabetic rats.ArticleItem Open Access Pathological Evaluation of Anti-tumour Effects of Withaferin A against Experimentally Induced Mammary Tumour in Rats(2020-08) Pratheepa, K; Balachandran, C; Sridhar, R; TANUVASWith the aim to explore the anti-tumour effect of Withaferin A in DMBA (7,12- dimethylbenz[a]anthracene) induced mammary tumour in rats, seventy two female Sprague-Dawley rats were equally distributed to control, DMBA, tamoxifen and Withaferin A groups. Tamoxifen, which is widely used as first-line drug in the treatment of estrogen positive breast cancer was taken as standard for comparison. The study was conducted for a period of 16 weeks. DMBA (5 mg/rat/week/per os) at 4 weekly doses were used for tumour induction. Piloerection was noticed after DMBA administration. Tumour latency, location, incidence, frequency, size, volume and weight were recorded. Hundred per cent tumour formation in DMBA alone administered animal was observed. No metastasis was recorded. Abdominal glands were most frequently affected in all DMBA administered groups. Withaferin A group showed 17% tumour inhibition and the number of tumours were almost equal to that of DMBA group. Higher incidence of carcinomas (65%) and lower incidence of benign (35%) mammary tumours were observed in Withaferin A group with maximum tumour frequency of seven tumours/rat when compared with tamoxifen group. Hence further investigations are required.